Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond

Purpose: Radiotherapy is integral in the management of hematological malignancies (HM). Standard radiotherapy dose fractionation regimens range between 20 and 50 Gy in 10–25 fractions over 2–5 weeks. This study presents the outcomes of patients with HM treated with hypofractionation radiotherapy (HF...

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Febin Antony, Arbind Dubey, Pamela Skrabek, Lung Fung Tsang, Pascal Lambert, Bohdan Bybel, Naseer Ahmed
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Subjects:	lymphomas hypofractionation radiotherapy
Online Access:	https://www.mdpi.com/1718-7729/31/1/25

Similar Items

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
by: Cheng Huang, et al.
Published: (2024-01-01)

Acute toxicity outcomes in Egyptian early-stage breast cancer: ultra-hypofractionated versus hypofractionated radiotherapy
by: Ahmed Magdy, et al.
Published: (2025-05-01)

Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
by: Ellery Koelker-Wolfe, et al.
Published: (2025-02-01)

Efficacy and Toxicity of Hypofractionated Palliative Radiotherapy for Breast Cancer Patients with Skin Invasion
by: Talha Maqsood, et al.
Published: (2023-08-01)

Weekly ultra-hypofractionated radiotherapy in localised prostate cancer
by: Nora Sundahl, et al.
Published: (2024-07-01)

Use of hypofractionated radiotherapy regimens after organ-sparing surgery for Stages I–IIA breast cancers
by: Yu. V. Efimkina, et al.
Published: (2014-08-01)

The Potential of Hypofractionated Radiotherapy: A Revolutionary Treatment for Anorectal Malignant Melanomas
by: Vandana Thakur, et al.
Published: (2025-01-01)

Hypofractionated radiotherapy regimens after organ-sparing surgery for stages I–IIa breast cancer
by: Yu. V. Efimkina, et al.
Published: (2014-08-01)

Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
by: Ioannis M. Koukourakis, et al.
Published: (2021-09-01)

Tumor volume changes after stereotactic, hypofractionated and conventional radiotherapy in paragangliomas of head and neck
by: Paweł J. Polanowski, et al.
Published: (2024-09-01)

Acute toxicity patterns and their management after moderate and ultra- hypofractionated radiotherapy for prostate cancer: A prospective cohort study
by: F. Sinzabakira, et al.
Published: (2024-09-01)

Hypofractionated Post-Prostatectomy Radiotherapy in 16 Fractions: A Single-Institution Outcome
by: Pavol Dubinsky, et al.
Published: (2023-07-01)

Carcinoma buccal mucosa treated with definitive hypofractionated accelerated radiotherapy: a retrospective analysis of treatment outcomes
by: Geethu Babu, et al.
Published: (2025-07-01)

Hypofractionation: The standard for external beam breast irradiation
by: Adrian Murray Brunt, et al.
Published: (2023-06-01)

A Prospective Study to Assess Response and Toxicity of Hypofractionated Palliative Radiotherapy in Advanced Inoperable Oropharyngeal Carcinoma
by: Ayush Naik, et al.
Published: (2025-07-01)

Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer
by: Janice Ser Huey Tan, et al.
Published: (2024-02-01)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
by: Jiang Xue-song, et al.
Published: (2012-03-01)

An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas
by: Michael Laursen, et al.
Published: (2018-06-01)

Effect of hypofractionated radiotherapy on lung functions in breast cancer patients
by: Enass A.A. Rezk, et al.
Published: (2023-01-01)

Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients
by: Yongkai Lu, et al.
Published: (2024-02-01)

Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma
by: Jiahua Lyu, et al.
Published: (2019-07-01)

Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma
by: Lindsey Greenlund, et al.
Published: (2023-10-01)

CBCT-Based Online Adaptive, Ultra-Hypofractionated Radiotherapy for Prostate Cancer: First Clinical Experiences
by: Georg Wurschi, et al.
Published: (2025-10-01)

Hypofractionated Radiotherapy for Prostate Cancer: A Comparative Study of Clinical Outcomes and Dosimetry Between Proton and Photon Therapy
by: Wu CT, et al.
Published: (2025-10-01)

A comparative study of hypofractionated and conventional radiotherapy in postmastectomy breast cancer patients
by: Kartick Rastogi, et al.
Published: (2018-01-01)

Ultra-Hypofractionated vs. Moderate Fractionated Whole Breast Three Dimensional Conformal Radiotherapy during the COVID-19 Pandemic
by: Olivera Ivanov, et al.
Published: (2022-05-01)

Hypofractionated versus conventional radiotherapy for head-and-neck cancer: A systematic review and meta-analysis
by: Arnab Roy, et al.
Published: (2025-01-01)

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity
by: Kaicheng Pan, et al.
Published: (2024-07-01)

Hypofractionation and Concomitant Boost in Ductal Carcinoma In Situ (DCIS): Analysis of a Prospective Case Series with Long-Term Follow-Up
by: Domenico Cante, et al.
Published: (2022-06-01)

Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma
by: Paolo Passoni, et al.
Published: (2024-07-01)

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity
by: Crosby Rock, et al.
Published: (2023-08-01)

Randomized Prospective Study Comparing Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node-Positive Breast Cancer
by: Mai Atef, et al.
Published: (2019-12-01)

Incidence of acute radiodermatitis in women with breast cancer undergoing hypofractionated radiotherapy
by: Laura Beatriz Sousa de Jesus Martelletti, et al.
Published: (2021-09-01)

A Study of Volumetric Variation in the Excision Cavity during Hypofractionated Whole Breast Radiotherapy
by: Ayatallah Youssief Mohammed, et al.
Published: (2023-04-01)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
by: Maria Chiara Lo Greco, et al.
Published: (2023-06-01)

Investigation of Ki-67 and Clinical Outcome in Feline Nasal Adenocarcinoma Treated Using Hypofractionated Radiotherapy
by: Premkamon Aonta, et al.
Published: (2024-12-01)

Clinical outcomes and prognostic factors of repeated conventional hypofractionated radiotherapy for recurrent intranasal tumors in dogs
by: Hirona Ueno, et al.
Published: (2025-02-01)

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity
by: Imjai Chitapanarux, et al.
Published: (2019-10-01)

Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery
by: Na Li, et al.
Published: (2025-03-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01)